Amlodipine/losartan - Hanmi Pharmaceutical

Drug Profile

Amlodipine/losartan - Hanmi Pharmaceutical

Alternative Names: Amlozaar; Amosartan; ARB/CCB; Bicartial; Branta; CCB/ARB; Cozaar XQ; HCP 0605; Ildusartán; Losartan/amlodipine - Hanmi Pharmaceutical; Sardip; Tozam; UI-15AML055MT

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Merck Sharp & Dohme
  • Class Antihypertensives; Dihydropyridines; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 07 Oct 2016 Chemical structure information added
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in Czech Republic (PO, Tablet)
  • 28 Oct 2015 Amlodipine/losartan licensed to Serenus Biotherapeutics in Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top